Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 180 people, planned
- Started
- 1 Feb 2022
- Expected to end
- 27 Feb 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use
- Usual Care (UC)
- Record updated
- 16 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Men and women age ≥ 18 years
- Diagnosis of chronic liver disease (CLD)
- Unhealthy alcohol use, defined as more than moderate amount of alcohol use within the prior 30 days by National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria defined as on average more than 1 drink/day (7 drinks per week) for women and more than 2 drinks per day (14 drinks per week) for men, or on average at least one heavy drinking day (4+ drinks in a day for women and 5+ for men) per week in the prior 30 days. A standard drink is ~14 g of alcohol
- Ability to access a telephone or a digital device (i.e., computer, tablet or smart phone)
Who cannot take part
- Severe medical or psychiatric conditions or evidence of acute alcohol intoxication preventing participation in the study
- Are currently enrolled in formal treatment for unhealthy alcohol use, excluding self or mutual-help groups (e.g., Alcoholics Anonymous)
- Women who are pregnant or breastfeeding or unwilling to use birth control
- Language preference other than English, Spanish or Chinese
- Unwilling or unable to provide informed consent
Where in United States
- University of California San FranciscoSan Francisco, United States
- Zuckerberg San Francisco General HospitalSan Francisco, United States
About the trial
What the trial wants to find out
The study consists of a randomized controlled trial evaluating the efficacy and feasibility of a stepped alcohol treatment using telemedicine on unhealthy alcohol use in patients with chronic liver disease receiving care in hepatology practices at three sites. Patients who meet eligibility criteria will be randomized to one of two study arms: 1) Stepped Alcohol Treatment (SAT) or, 2) Usual Care (UC). Participants will be randomized separately by site. SAT includes 3 sessions of motivational interviewing followed by referral to addiction medicine for patients who do not reduce unhealthy drinking. Trial outcome measures will be complete at 6 and 12 months following baseline enrollment.
The 2 groups in the trial
- Stepped alcohol intervention (SAT) to reduce unhealthy alcohol useTreatment being tested
For participants randomized to SAT, consistent with stepped care, treatment will begin with lower intensity services that are stepped up, if necessary, at a predefined time point. Step 1 consists of three motivational interviewing (MI)sessions delivered every 2 weeks. At the 3-month assessment, those with non-response to MI, defined as continued unhealthy alcohol use in the prior 14 days, will be referred to on site physician managed addiction specialty services (Step 2) for higher intensity services.
- Usual Care (UC)Existing treatment, for comparison
UC participants will receive their usual services in hepatology. They will also be given publicly available patient education materials regarding risk associated with unhealthy drinking (mail/email or in-person if desired) and will be asked to follow up with their physician should they have questions about information provided in the handouts. UC participants' hepatology provider will be notified if AUDIT-C scores are greater than 3 at baseline. All UC participants will have access to alcohol and other substance use treatment available to patients at their respective sites.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of the Coronavirus 2019 (COVID-19) Pandemic on Patient Outcomes, Telehealth Care Delivery, and Treatment for Unhealthy Alcohol Use in Vulnerable Patients With Advanced Liver Disease Across Two Healthcare Systems
- Record updated
- 16 October 2026